+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of abrocitinib oral suspension, with or without topical medications, in children aged 2 years and older who have moderate-to-severe atopic dermatitis. This Phase 3 open-label study includes two groups children who previously completed abrocitinib studies and those who have never participated in such studies. The study aims to better understand the treatments impact over an extended period. Participants will receive abrocitinib oral suspension throughout the study, which may last up to 24 months or until the medicine becomes commercially available, whichever happens first. The study will enroll up to 500 children globally, split between those continuing from previous trials and new participants aged 6 to under 12 years. All children will receive the same study treatment during this period. Throughout the study, participants will be closely monitored with regular assessments of safety, including treatment-related side effects and laboratory tests. Researchers will also evaluate skin condition improvements using various scales and indexes, itch intensity, quality of life measures, and the need for additional topical treatments. This comprehensive follow-up will last up to two years to track long-term effects and safety outcomes.

Age: 2Years - 11YearsAll GendersPhase 3
39 locations
I

Actively Recruiting

Researchers are studying abrocitinib to see if it improves eczema symptoms and is safe for children aged 6 to less than 12 years who have moderate-to-severe eczema. The study is a phase 3, randomized, double-blind, placebo-controlled trial that compares abrocitinib with a placebo. Participants will be randomly assigned to receive either the test medicine or placebo for 16 weeks, with the entire study lasting about 24 weeks. Participants will receive abrocitinib or placebo as a liquid oral suspension. They will use an electronic diary, similar to a cell phone, to record questionnaire responses and receive daily reminders to take the medication and complete questionnaires. They will also wear a wrist device resembling a childrens watch to monitor scratching caused by their eczema. The study involves regular clinic visits, laboratory tests, physical exams, and vital sign monitoring to assess health and treatment effects. During the study, researchers will assess eczema severity using validated scales such as the Investigators Global Assessment and the Eczema Area and Severity Index at week 12. They will also monitor itch severity and improvement through a numerical rating scale at weeks 2 and 12. Health checks including height, weight, temperature, blood pressure, and heart rate will be performed. Participants will have scheduled visits and phone calls with study staff to track progress and safety throughout the study period.

Age: 6Years - 11YearsAll GendersPhase 3
47 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations